These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [From heparin to heparins: toward new therapeutic perspectives?]. Molho P; Tobelem G Biomed Pharmacother; 1987; 41(4):171-5. PubMed ID: 3620582 [TBL] [Abstract][Full Text] [Related]
4. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Brieger D; Dawes J Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589 [TBL] [Abstract][Full Text] [Related]
5. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities. Peyrou V; Béguin S; Boneu B; Hemker HC Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588 [TBL] [Abstract][Full Text] [Related]
6. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route. Millet J; Jouault SC; Mauray S; Theveniaux J; Sternberg C; Boisson Vidal C; Fischer AM Thromb Haemost; 1999 Mar; 81(3):391-5. PubMed ID: 10102467 [TBL] [Abstract][Full Text] [Related]
7. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay. Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456 [TBL] [Abstract][Full Text] [Related]
8. Fractionation and structural features of two heparin families with high antithrombotic, antilipemic and anticoagulant activities. Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP; Casu B; Torri G Arzneimittelforschung; 1985; 35(8):1215-9. PubMed ID: 4074437 [TBL] [Abstract][Full Text] [Related]
9. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes. Nguyen-Ho P; Levine GN Panminerva Med; 2002 Jun; 44(2):115-22. PubMed ID: 12032429 [TBL] [Abstract][Full Text] [Related]
10. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038 [TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277 [TBL] [Abstract][Full Text] [Related]
12. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. Agnelli G; Sonaglia F Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128 [TBL] [Abstract][Full Text] [Related]
13. Influence of low molecular weight heparin on the hemostatic system after abdominal surgery. Schmitz-Huebner U; Rüschemeyer C; Schulte H; van de Loo J Thromb Haemost; 1985 Jun; 53(3):297-300. PubMed ID: 3901387 [TBL] [Abstract][Full Text] [Related]